key: cord-0787866-gy255y56 authors: Miyashita, Naoyuki; Nakamori, Yasushi; Ogata, Makoto; Fukuda, Naoki; Yamura, Akihisa; Ishiura, Yoshihisa; Nomura, Shosaku title: Clinical features of nursing and healthcare-associated pneumonia due to COVID-19 date: 2022-03-19 journal: J Infect Chemother DOI: 10.1016/j.jiac.2022.03.010 sha: 27668298bfa74a228fa9855563ced0f9beea25d5 doc_id: 787866 cord_uid: gy255y56 INTRODUCTION: The objective of this study was to clarify the clinical differences between nursing and healthcare-associated pneumonia (NHCAP) and community-acquired pneumonia (CAP) due to COVID-19. We also investigated the clinical characteristics to determine whether there is a difference between the variant and non-variant strain in patients with NHCAP due to COVID-19. In addition, we analyzed the clinical outcomes in NHCAP patients with mental disorders who were hospitalized in a medical institution for treatment of mental illness. METHODS: This study was conducted at five institutions and assessed a total of 836 patients with COVID-19 pneumonia (154 cases were classified as NHCAP and 335 had lineage B.1.1.7.). RESULTS: No differences in patient background, clinical findings, disease severity, or outcomes were observed in patients with NHCAP between the non-B.1.1.7 group and B.1.1.7 group. The median age, frequency of comorbid illness, rates of intensive care unit stay, and mortality rate were significantly higher in patients with NHCAP than in those with CAP. Among the patients with NHCAP, the mortality rate was highest at 37.5% in patients with recent cancer treatment, followed by elderly or disabled patients receiving nursing care (24.3%), residents of care facilities (23.0%), patients receiving dialysis (13.6%), and patients in mental hospitals (9.4%). CONCLUSIONS: Our results demonstrated that there were many differences in the clinical characteristics between NHCAP patients and CAP patients due to COVID-19. It is necessary to consider the prevention and treatment content depending on the presence or absence of applicable criteria for NHCAP. Pneumonia including aspiration pneumonia is the third leading cause of mortality in Japan and most cases are elderly persons (≥65 years old). A major feature of Japan is that there are high percentage of elderly persons. In line with the actual situation in Japan, the Japan Respiratory Society (JRS) guidelines defined a new pneumonia category as the nursing and healthcare-associated pneumonia (NHCAP) [1] separate from community-acquired pneumonia (CAP) [2] . To confirm the validity of new category, many Japanese researchers have verified NHCAP and made the differences clear between NHCAP and CAP [3] [4] [5] [6] [7] [8] . Median age and frequency of comorbid illness were significantly higher in patients with NHCAP than those with CAP. Several differences were also observed among four NHCAP subgroups. Coronavirus disease 2019 , caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in 2019 [9] . Approximately 5-20% of patients with COVID-19 develop severe life-threatening pneumonia with respiratory failure [9] . SARS-CoV-2 causes frequent outbreaks in facilities such as welfare facilities for persons with disabilities, long-term care health facilities, and mental hospitals that meet the criteria for NHCAP. Older age and comorbid illness are relevant to both worse severity and fatal outcome in patients with COVID-19 [10] . In addition, several studies demonstrated increased risks of SARS-CoV-2 infection, disease severity, and mortality in persons with mental disorders [11] [12] [13] [14] . The objective of this study was to clarify the clinical differences between NHCAP and CAP due to COVID-19. In particular, we focused on patient background, clinical findings, disease severity, and outcomes in patients with NHCAP. We also investigated the clinical characteristics to determine whether there was a difference between variant and nonvariant strains in patients with NHCAP due to COVID-19. In addition, we analyzed the clinical outcomes in NHCAP patients with mental disorders who hospitalized in a medical institution for the treatment of mental illness. The present study was conducted at five institutions (Kansai Medical University Hospital, Kansai Medical University Medical Center, Kansai Medical University Kori Hospital, Kansai Medical University Kuzuha Hospital, and Kansai Medical University Temmabashi General Clinic) between February 2020 and June 2021. We enrolled adult patients diagnosed with NHCAP and CAP, defined in accordance with the JRS guidelines [1, 2] . COVID-19 was diagnosed with positive reverse transcription polymerase chain reaction results from sputum or nasopharyngeal swab specimens in accordance with the protocol recommended by the National Institute of Infectious Diseases, Japan. From March 2021, a new lineage of the SARS-CoV-2, named B.1.1.7 [15] , had rapidly spread throughout Japan and reached almost 100% replacement by the B.1.1.7 variant in June 2021. Lineage B.1.1.7 includes multiple changes, including an N501Y (Asn501Tyr) substitution in the spike protein that enhances binding to the human ACE2 receptor, through which the virus enters the cell [16, 17] . Thus, we analyzed the non-B.1.1.7 and B.1.1.7 groups separately. The severity of pneumonia was evaluated using predictive rules via the A-DROP system proposed by the JRS guidelines: age over 70 years in male and over 75 years in female, dehydration, respiratory failure, orientation disturbance, and low blood pressure [2, 18] . Informed consent was obtained from all patients, and the study protocol was approved by the Ethics Committee of Kansai Medical University (approval number 2020319). Statistical analysis was performed using Stat View version 5.0. (SAS Institute Inc, Cary, NC, USA). The incidence of clinical findings was analyzed using Fisher's Exact test. Continuous variables were compared using the Student's t-test when variables were normally distributed, and the Mann-Whitney U test was used when variables were non-normally distributed. The data for a total of 836 patients (538 men and 298 women with a median age of 64 years) with COVID-19 pneumonia were analyzed. Of the 836 COVID-19 pneumonia patients, 335 had lineage B.1.1.7 and 154 cases were classified as NHCAP [1] . Of these, 79 (15.8%) cases were non-B.1.1.7 group and 75 (22.4%) cases were B.1.1.7 group, respectively (Table 1) . Among the NHCAP criteria, there were no differences between the two groups ( Table 1 ). In Group A, 32 cases had mental disorders and who were hospitalized in a medical institution for the treatment of mental illness. Tables 2 and 3 show the underlying conditions and clinical findings of NHCAP and CAP patients in the non-B.1.1.7 and B.1.1.7 groups at the first examination, respectively. Patients with NHCAP were significantly older than those with CAP (p < 0.0001), but the male/female ratio did not differ between NHCAP and CAP in both the non-B.1.1.7 and B.1.1.7 groups. Among co-morbid conditions, cerebrovascular disease, chronic renal disease, and neoplastic disease were significantly more frequent in patients with NHCAP compared with those with CAP in both groups. Among clinical signs and symptoms, many symptoms were less frequent in patients with NHCAP compared with those with CAP in both groups. The severity on admission of NHCAP and CAP was assessed by means of the A-DROP systems of the JRS (Tables 2 and 3 ). The average A-DROP scores in patients with NHCAP were significantly higher than in patients with CAP in both non-B.1.1.7 and B.1.1.7 groups (non-B.1.1.7 group, CAP 0.95 ± 1.12 versus NHCAP 2.01 ± 0.79, p < 0.0001; B.1.1.7 group, CAP 1.31 ± 0.96 versus NHCAP 1.83 ± 0.82, p = 0.0122). Pneumonia severity was also evaluated using predictive rules with a 5-point scoring system for hospital-acquired pneumonia from the JRS: I-ROAD (immunodeficiency, age, respiratory failure, orientation disturbance, and dehydration) [19] . The average I-ROAD scores in patients with NHCAP were also significantly higher than those of patients with CAP in both groups. Rates of intensive care unit (ICU) stay and in-hospital mortality were significantly higher in patients with NHCAP compared with those with CAP in both groups (Tables 2 and 3 ). In patients with NHCAP, these rates were similar in the non-B. No clinical differences were observed in patients with NHCAP between the non-B.1.1.7 and B.1.1.7 groups. Thus, we performed a subanalysis in four NHCAP subgroups (Group A to D) using all NHCAP patients. Several differences were observed among the four NHCAP subgroups (Table 4 ). NHCAP patients in Group C were significantly older than those in patients in Groups B and D (p < 0.0001). Rates of ICU stay were significantly higher in patients in Group D than patients in Groups A (p = 0.011) and C (p = 0.0034). Mortality rate were highest in Group C (24.3%), followed by Group D (20.5%), Group B (20.0%), and Group A (13.3%). Table 5 shows the underlying conditions and clinical findings in 32 patients with mental disorders who were hospitalized in a medical institution for the treatment of mental illness (22 schizophrenia, 4 mental retardation, 4 depressive disorders and 2 neurotic disorders), 122 patients with NHCAP excluding mental hospitals and 682 patients with CAP, respectively. Patients in mental hospitals were significantly younger than those with NHCAP (p < 0.0001), but similar to those with CAP. The frequency of comorbid illness in patients in mental hospitals was significantly lower than those with NHCAP (p < 0.0001), but the similar to those with CAP. The average A-DROP scores in patients from mental hospitals were significantly higher than that in patients with CAP (Mental hospital 1.56 ± 0.83 versus CAP 1.02 ± 1.08, p = 0.0413). Rates of ICU stay in patients in mental hospitals were higher than that in patients with CAP (Mental hospital 53.1% versus CAP 35.2%), but these differences did not reach statistical significance. Rates of in-hospital mortality in patients from mental hospitals was significantly higher than that of patients with CAP (Mental hospital 9.4% versus CAP 2.3%, p = 0.0486). COVID-19 mainly occurs in the outpatient setting and CAP is more frequent than NHCAP among types of pneumonia. However, many outbreaks due to SARS-CoV-2 have occurred in nursing homes and mental hospitals, thereby meeting the criteria for NHCAP. The present results revealed differences in patient background, clinical findings, disease severity, and clinical outcomes between NHCAP and CAP due to COVID-19. The median age and frequency of comorbid illness, which are associated with greater severity of COVID-19 [10] , were significantly higher in patients with NHCAP than those with CAP (p < 0.0001). Rates of ICU stay and in-hospital mortality were also significantly higher in patients with NHCAP than those with CAP. These differences were similar to previous reports that investigated the differences in NHCAP and CAP due to bacterial infection [3] [4] [5] [6] [7] [8] 20, 21] . Our results also demonstrated that there were no differences in the clinical characteristics of patients with NHCAP between the non-B.1.1.7 group and B.1.1.7 group. Thus, giving priority for SARS-CoV-2 vaccination to elderly people and people with comorbid illnesses is thought to be reasonable. In fact, SARS-CoV-2 vaccination of people who met the NHCAP criteria was successful in the 5th wave of COVID-19 in Japan because number of severely ill patients and deaths due to COVID-19 in the elderly persons was markedly reduced [22] . Patients with mental disorders who are hospitalized in a medical institution for treatment of mental illness were included in NHCAP Group A. Our previous studies demonstrated that the pneumonia severity and mortality rate in patients in mental hospitals were lowest among the patients NHCAP and similar to those with CAP [20, 21] . These findings may be related to the younger age and lower frequency of comorbid illnesses in patients in mental hospitals, as observed in this study. However, in the present study, the ICU stay and mortality rate were higher in patients in mental hospitals than those of patients with CAP (Table 5) , as reported other studies [11] [12] [13] [14] . Thus, it was appropriate to add patients with severe mental disorders to the vaccination priority program. Within Group D, 16 patients were receiving regular endovascular treatment with anti-cancer drugs as an outpatient and 28 patients were receiving dialysis. A large Japanese cohort study demonstrated that patients with solid tumors or receiving dialysis experienced more-severe COVID-19 [10] . Among patients with NHCAP, the mortality rate was highest at 37.5% in patients with recent cancer treatment, followed by elderly or disabled people who were receiving nursing care with performance status scores of 3 or 4 (Group C, 24.3%), residents of an extended care facility or long-term care health facility (Group A, 23.0%), patients receiving dialysis (13.6%), and patients with mental disorders who were hospitalized in a medical institution for the treatment of mental illness (9.4%). Our previous study demonstrated that the mortality rate was higher in patients in Group A and C than Group D [20] . Chavez-MacGregor and colleagues found that patients with recent cancer treatment and COVID-19 had a significantly higher risk of adverse outcomes (odds ratio: death 1.74, ICU stay 1.69, and hospitalization 1.19) , and patients with no recent cancer treatment had similar outcomes to those without cancer [23] . However, the outcomes in patients with recent cancer treatment and COVID-19 are still controversial [24] [25] [26] [27] . In this study, cases of pneumonia mixed with other microorganisms were excluded because small sample size. A systematic review and metaanalysis demonstrated the bacterial co-infection and secondary infection in patients with COVID-19 was observed in 3.5%-7% [28, 29] . Our study demonstrated the bacterial co-infection with COVID-19 was observed in 2.1%. The prevalence rate of co-infection may different according to pneumonia severity. Our study had several limitations. The main purpose of this study was to clarify the differences between NHCAP and CAP due to COVID-19. In addition, we performed a subanalysis in four NHCAP subgroups (Groups A to D). Thus, sample size was small in each of the NHCAP subgroups. In particular, we were unable to evaluate Group B patients who has been discharged from a hospital within the preceding 90 days. Mortality rate may be affected in patients with recent cancer treatment, patients receiving dialysis, and patients in mental hospitals. Further studies with a larger sample size in each NHCAP subgroups are needed. In conclusion, the median age, frequency of comorbid illness, rates of ICU stay, and mortality rate were significantly higher in patients with NHCAP than in those with CAP due to COVID-19. These findings were identical between the non-B.1.1.7 group and B.1.1.7 group. It is necessary to consider the prevention and treatment content depending on the presence or absence of applicable criteria for NHCAP. The study protocol was approved by the Ethics Committee at Kansai Medical University and all participating facilities. Informed consent was obtained from all individual participants in the study. No funding was received. All the authors conceived the study, participated in its design and coordination, and collected and managed the data, including quality control. NM, YN and SN drafted the manuscript, and all authors contributed substantially to its revision. All the authors read and approved the final manuscript. The data will not be shared because of participant confidentiality. Not applicable. Clinical practice guidelines for nursing-and healthcare-associated pneumonia (NHCAP) Committee for The Japanese Respiratory Society guidelines for the management of respiratory infections. Guidelines for the management of community acquired pneumonia in adults Clinical characteristics of nursing and healthcare-associated pneumonia: a Japanese variant of healthcare-associated pneumonia A prospective comparison of nursing-and healthcare-associated pneumonia (NHCAP) with community-acquired pneumonia (CAP) The definition of healthcare-associated pneumonia (HCAP) is insufficient for the medical environment in Japan: a comparison of HCAP and nursing and healthcareassociated pneumonia (NHCAP) Comparison of clinical profile in elderly patients with nursing and healthcare-associated pneumonia, and those with community-acquired pneumonia Reevaluation of the Japanese guideline for healthcare-associated pneumonia in a medium-size community hospital in Japan Clinical features of healthcare-associated pneumonia (HCAP) in Japanese community hospital: comparisons among nursing home-acquired pneumonia (NHAP), HCAP other than NHAP, and community-acquired pneumonia Virology, transmission, and pathogenesis of SARS-CoV-2 Risk factors for severity on admission and the disease progression during hospitalization in a large cohort of patients with COVID-19 in Japan Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study Association of psychiatric disorders with mortality among patients with COVID-19 Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations COVID-19: new coronavirus variant is identified in UK Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study A-DROP system for prognostication of NHCAP inpatients The committee for the Japanese Respiratory Society guidelines in management of respiratory infections. The Japanese Respiratory Society guideline for the management of hospital-acquired pneumonia in adults Clinical features and the role of atypical pathogens in nursing and healthcare-associated pneumonia (NHCAP): differences between teaching university hospital and community hospital Detection failure rate of chest radiography for the identification of nursing and healthcareassociated pneumonia Ministry of health, labour and welfare. 50 th Advisory board of countermeasures for COVID-19 infection Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Correction: impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis Co-infections in people with COVID-19: a systematic review and meta-analysis The authors declare that they have no competing interests.